{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:09:52Z","timestamp":1791090592999,"version":"4.1.0"},"reference-count":111,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1016\/j.humpath.2008.02.004","type":"journal-article","created":{"date-parts":[[2008,6,4]],"date-time":"2008-06-04T08:23:27Z","timestamp":1212567807000},"page":"795-810","source":"Crossref","is-referenced-by-count":59,"title":["The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms"],"prefix":"10.1016","volume":"39","author":[{"given":"Cristina A.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2008.02.004_bib1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood.V95.1.19","article-title":"The Jak-Stat pathway in normal and perturbed hematopoiesis","volume":"95","author":"Ward","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2008.02.004_bib2","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1074\/jbc.270.10.4979","article-title":"The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl","volume":"270","author":"Drachman","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.humpath.2008.02.004_bib3","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0092-8674(93)90415-M","article-title":"Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase","volume":"74","author":"Argetsinger","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.humpath.2008.02.004_bib4","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0092-8674(00)81168-X","article-title":"Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis","volume":"93","author":"Neubauer","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.humpath.2008.02.004_bib5","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0092-8674(00)81167-8","article-title":"Jak2 is essential for signaling through a variety of cytokine receptors","volume":"93","author":"Parganas","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.humpath.2008.02.004_bib6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.exphem.2003.11.006","article-title":"JAK2 contributes to the intrinsic capacity of primary hematopoietic cells to respond to stem cell factor","volume":"32","author":"Radosevic","year":"2004","journal-title":"Exp Hematol"},{"key":"10.1016\/j.humpath.2008.02.004_bib7","doi-asserted-by":"crossref","first-page":"8429","DOI":"10.1073\/pnas.90.18.8429","article-title":"Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction","volume":"90","author":"Silvennoinen","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.humpath.2008.02.004_bib8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0092-8674(93)90414-L","article-title":"JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin","volume":"74","author":"Witthuhn","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.humpath.2008.02.004_bib9","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1073\/pnas.86.5.1603","article-title":"Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction","volume":"86","author":"Wilks","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.humpath.2008.02.004_bib10","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1182\/blood-2005-03-1287","article-title":"On the molecular origins of the chronic myeloproliferative disorders: it all makes sense","volume":"105","author":"Kaushansky","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2008.02.004_bib11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.gde.2006.12.009","article-title":"Jak2: normal function and role in hematopoietic disorders","volume":"17","author":"Ihle","year":"2007","journal-title":"Curr Opin Genet Dev"},{"key":"10.1016\/j.humpath.2008.02.004_bib12","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.bbrc.2004.10.071","article-title":"Determination of the transphosphorylation sites of Jak2 kinase","volume":"325","author":"Matsuda","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.humpath.2008.02.004_bib13","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/blood-2005-06-2413","article-title":"The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor","volume":"107","author":"Lucet","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2008.02.004_bib14","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/protein\/15.9.727","article-title":"Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7","volume":"15","author":"Giordanetto","year":"2002","journal-title":"Protein Eng"},{"key":"10.1016\/j.humpath.2008.02.004_bib15","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0968-0004(98)01237-7","article-title":"The FERM domain: a unique module involved in the linkage of cytoplasmic proteins to the membrane","volume":"23","author":"Chishti","year":"1998","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.humpath.2008.02.004_bib16","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1126\/science.1071545","article-title":"A road map for those who don't know JAK-STAT","volume":"296","author":"Aaronson","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.humpath.2008.02.004_bib17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/10428190500301348","article-title":"JAK2 V617F in myeloid disorders: what do we know now, and where are we headed?","volume":"47","author":"Nelson","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.humpath.2008.02.004_bib18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0301-472X(01)00789-5","article-title":"Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera","volume":"30","author":"Kralovics","year":"2002","journal-title":"Exp Hematol"},{"key":"10.1016\/j.humpath.2008.02.004_bib19","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.humpath.2008.02.004_bib20","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2008.02.004_bib21","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.humpath.2008.02.004_bib22","doi-asserted-by":"crossref","first-page":"22788","DOI":"10.1074\/jbc.C500138200","article-title":"Identification of an acquired JAK2 mutation in polycythemia vera","volume":"280","author":"Zhao","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.humpath.2008.02.004_bib23","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2008.02.004_bib24","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"106","author":"Jones","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2008.02.004_bib25","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1182\/blood-2006-04-018259","article-title":"Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia","volume":"108","author":"Scott","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2008.02.004_bib26","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1055\/s-2007-976165","article-title":"Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F","volume":"33","author":"Tefferi","year":"2007","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.humpath.2008.02.004_bib27","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1182\/blood-2005-09-3900","article-title":"X-inactivation\u2013based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET\/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis","volume":"107","author":"Levine","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2008.02.004_bib28","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/sj.leu.2404209","article-title":"A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis","volume":"20","author":"Vannucchi","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2008.02.004_bib29","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1182\/blood-2005-12-013748","article-title":"Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation","volume":"108","author":"Campbell","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2008.02.004_bib30","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.21645","article-title":"The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera","volume":"106","author":"Tefferi","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2008.02.004_bib31","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood-2005-05-1898","article-title":"The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia","volume":"106","author":"Levine","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2008.02.004_bib32","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood-2006-02-005751","article-title":"Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation","volume":"108","author":"Szpurka","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2008.02.004_bib33","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1038\/sj.leu.2404232","article-title":"Reply to Kremer M et al., the JAK2 V617F mutation occurs frequently in myelodysplastic\/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis","volume":"20","author":"Ohyashiki","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2008.02.004_bib34","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1038\/sj.leu.2403989","article-title":"The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients","volume":"19","author":"Ohyashiki","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2008.02.004_bib35","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2005-03-1183","article-title":"The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \u201catypical\u201d myeloproliferative disorders and myelodysplastic syndromes","volume":"106","author":"Steensma","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2008.02.004_bib36","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1038\/sj.leu.2403903","article-title":"JAK2 Val617Phe activating tyrosine kinase mutation in juvenile myelomonocytic leukemia","volume":"19","author":"Tono","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2008.02.004_bib37","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/sj.leu.2404484","article-title":"JAK2 V617F mutation is a rare event in juvenile myelomonocytic leukemia","volume":"21","author":"Zecca","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2008.02.004_bib38","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1038\/sj.leu.2404373","article-title":"The JAK2 V617F mutation is rare in RARS but common in RARS-T","volume":"20","author":"Ceesay","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2008.02.004_bib39","first-page":"719","article-title":"Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic\/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis","volume":"91","author":"Remacha","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.humpath.2008.02.004_bib40","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3324\/haematol.11581","article-title":"JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis","volume":"93","author":"Schmitt-Graeff","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.humpath.2008.02.004_bib41","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1182\/blood-2006-03-008227","article-title":"The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS)","volume":"108","author":"Boissinot","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2008.02.004_bib42","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1182\/blood-2006-04-014746","article-title":"Pediatric patients with essential thrombocythemia are mostly polyclonal and V617FJAK2 negative","volume":"108","author":"Randi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2008.02.004_bib43","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1182\/blood-2006-12-061135","article-title":"Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation","volume":"109","author":"Hussein","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2008.02.004_bib44","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(07)70294-2","article-title":"Insights into JAK2-V617F mutation in CML","volume":"8","author":"Busche","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.humpath.2008.02.004_bib45","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/sj.leu.2404730","article-title":"Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis","volume":"21","author":"Bornhauser","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2008.02.004_bib46","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/sj.leu.2404591","article-title":"Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia","volume":"21","author":"Inami","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2008.02.004_bib47","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1182\/blood-2007-01-071068","article-title":"Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation","volume":"110","author":"Passamonti","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2008.02.004_bib48","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2007-07-099184","article-title":"JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis","author":"Barosi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2008.02.004_bib49","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden","volume":"21","author":"Vannucchi","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2008.02.004_bib50","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2008.02.004_bib51","first-page":"664","article-title":"Clinical significance of JAK2V617F homozygosity in the chronic myeloproliferative disorders. A study on 1306 patients","volume":"108","author":"Vannucchi","year":"2006"},{"key":"10.1016\/j.humpath.2008.02.004_bib52","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2141.2007.06497.x","article-title":"The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders","volume":"136","author":"Larsen","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.humpath.2008.02.004_bib53","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2006-03-007146","article-title":"Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis","volume":"109","author":"Delhommeau","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2008.02.004_bib54","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/sj.onc.1209163","article-title":"The JAK2 V617F mutation in de novo acute myelogenous leukemias","volume":"25","author":"Lee","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.humpath.2008.02.004_bib55","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1182\/blood-2005-09-3644","article-title":"Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7","volume":"107","author":"Frohling","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2008.02.004_bib56","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/sj.leu.2404465","article-title":"JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)\/ AML1-ETO\u2013positive AML","volume":"21","author":"Schnittger","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2008.02.004_bib57","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/blood-2006-12-062125","article-title":"Leukemic blasts in transformed JAK2-V617F\u2013positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation","volume":"110","author":"Theocharides","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2008.02.004_bib58","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1365-2141.2005.05697.x","article-title":"The V617F mutation in Jak2 is not found in childhood acute lymphoblastic leukaemia","volume":"130","author":"Sulong","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.humpath.2008.02.004_bib59","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.leu.2404036","article-title":"Absence of the JAK2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma","volume":"20","author":"Melzner","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2008.02.004_bib60","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2008.02.004_bib61","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/sj.leu.2404810","article-title":"Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera","volume":"21","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2008.02.004_bib62","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1182\/blood-2007-05-092502","article-title":"A new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis","volume":"110","author":"Colaizzo","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2008.02.004_bib63","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/sj.leu.2404419","article-title":"Detection of a new JAK2 D620E mutation in addition to V617F in a patient with polycythemia vera","volume":"20","author":"Grunebach","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2008.02.004_bib64","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1038\/sj.leu.2404325","article-title":"Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E","volume":"20","author":"Schnittger","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2008.02.004_bib65","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.leu.2404060","article-title":"Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia","volume":"20","author":"Kratz","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2008.02.004_bib66","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1182\/blood-2006-09-045963","article-title":"Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia","volume":"109","author":"Malinge","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2008.02.004_bib67","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1182\/blood-2006-04-014712","article-title":"JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model","volume":"108","author":"Mercher","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2008.02.004_bib68","doi-asserted-by":"crossref","first-page":"7248","DOI":"10.1038\/sj.onc.1208850","article-title":"The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene","volume":"24","author":"Bousquet","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.humpath.2008.02.004_bib69","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1038\/sj.leu.2403879","article-title":"PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation","volume":"19","author":"Murati","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2008.02.004_bib70","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1158\/0008-5472.CAN-04-4263","article-title":"The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2","volume":"65","author":"Reiter","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2008.02.004_bib71","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/gcc.20235","article-title":"A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia","volume":"44","author":"Griesinger","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.humpath.2008.02.004_bib72","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.278.5341.1309","article-title":"A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia","volume":"278","author":"Lacronique","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.humpath.2008.02.004_bib73","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1182\/blood.V90.7.2535","article-title":"Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia","volume":"90","author":"Peeters","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2008.02.004_bib74","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/sj.leu.2404292","article-title":"The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors","volume":"20","author":"Sidon","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2008.02.004_bib75","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/sj.leu.2404007","article-title":"Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"20","author":"McClure","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2008.02.004_bib76","doi-asserted-by":"crossref","first-page":"42","DOI":"10.2353\/jmoldx.2007.060083","article-title":"Development of a quantitative real-time polymerase chain reaction assay for the detection of the JAK2 V617F mutation","volume":"9","author":"Wolstencroft","year":"2007","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.humpath.2008.02.004_bib77","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1373\/clinchem.2006.066886","article-title":"Combined locked nucleic acid and molecular beacon technologies for sensitive detection of the JAK2V617F somatic single-base sequence variant","volume":"52","author":"Sidon","year":"2006","journal-title":"Clin Chem"},{"key":"10.1016\/j.humpath.2008.02.004_bib78","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/humu.10078","article-title":"Pyrosequencing: an accurate detection platform for single nucleotide polymorphisms","volume":"19","author":"Fakhrai-Rad","year":"2002","journal-title":"Hum Mutat"},{"key":"10.1016\/j.humpath.2008.02.004_bib79","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood-2005-05-1800","article-title":"JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia","volume":"106","author":"Jelinek","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2008.02.004_bib80","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/sj.leu.2404123","article-title":"JAK2 V617F mutation, PRV-1 overexpression and endogenous erythroid colony formation show different coexpression patterns among Ph-negative chronic myeloproliferative disorders","volume":"20","author":"Bellosillo","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2008.02.004_bib81","unstructured":"Florensa L, Besses C, Woessner S, et al., Endogenous megakaryocyte and erythroid colony formation from blood in essential thrombocythaemia. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, UK 9, 271, 1995."},{"key":"10.1016\/j.humpath.2008.02.004_bib82","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1182\/blood-2005-04-1515","article-title":"The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients","volume":"106","author":"Goerttler","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2008.02.004_bib83","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1182\/blood-2006-03-008805","article-title":"Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression","volume":"108","author":"Moliterno","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2008.02.004_bib84","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2007.06565.x","article-title":"Anaemia characterises patients with myelofibrosis harbouring Mpl mutation","volume":"137","author":"Guglielmelli","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.humpath.2008.02.004_bib85","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.humpath.2008.02.004_bib86","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2008.02.004_bib87","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1365-2141.2006.06348.x","article-title":"Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time","volume":"135","author":"Lasho","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.humpath.2008.02.004_bib88","first-page":"224","article-title":"Karyotype and molecular cytogenetic studies in polycythemia vera","volume":"4","author":"Andrieux","year":"2005","journal-title":"Curr Hematol Rep"},{"key":"10.1016\/j.humpath.2008.02.004_bib89","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s00277-004-0977-1","article-title":"Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information","volume":"84","author":"Bacher","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.humpath.2008.02.004_bib90","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel","volume":"110","author":"Tefferi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2008.02.004_bib91","series-title":"Pathology and genetics of tumours of haematopoietic and lymphoid tissue","author":"WHO","year":"2001"},{"key":"10.1016\/j.humpath.2008.02.004_bib92","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1309\/JA1WD8JNVLGYNQYE","article-title":"JAK2 V617F mutation in patients with catastrophic intra-abdominal thromboses","volume":"127","author":"McMahon","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2008.02.004_bib93","first-page":"1712","article-title":"Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome","volume":"91","author":"Smalberg","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.humpath.2008.02.004_bib94","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/hep.21435","article-title":"Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis","volume":"44","author":"Primignani","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.humpath.2008.02.004_bib95","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1055\/s-2006-939432","article-title":"Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: diagnosis and management","volume":"32","author":"Briere","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.humpath.2008.02.004_bib96","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1053\/j.gastro.2006.04.008","article-title":"Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome","volume":"130","author":"Patel","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.humpath.2008.02.004_bib97","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/jmg.2006.048371","article-title":"Gain-of-function gene mutations and venous thromboembolism: distinct roles in different clinical settings","volume":"44","author":"Colaizzo","year":"2007","journal-title":"J Med Genet"},{"key":"10.1016\/j.humpath.2008.02.004_bib98","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1538-7836.2007.02424.x","article-title":"Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders","volume":"5","author":"De Stefano","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.humpath.2008.02.004_bib99","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/MOH.0b013e3282861d1b","article-title":"JAK2 V617F: implications for thrombosis in myeloproliferative diseases","volume":"14","author":"Hexner","year":"2007","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.humpath.2008.02.004_bib100","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00277-007-0351-1","article-title":"JAK2(V617F) positive early stage myeloproliferative disease (essential thrombocythemia) as the cause of portal vein thrombosis in two middle-aged women: therapeutic implications in view of the literature","volume":"86","author":"Michiels","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.humpath.2008.02.004_bib101","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1538-7836.2007.02384.x","article-title":"JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis","volume":"5","author":"Regina","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.humpath.2008.02.004_bib102","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/sj.leu.2404710","article-title":"JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder","volume":"21","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"issue":"12 Suppl","key":"10.1016\/j.humpath.2008.02.004_bib103","first-page":"ECR57","article-title":"MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count","volume":"91","author":"Steensma","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.humpath.2008.02.004_bib104","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/sj.leu.2404755","article-title":"The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosis","volume":"21","author":"Pemmaraju","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2008.02.004_bib105","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/sj.leu.2404649","article-title":"A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis","volume":"21","author":"Bellosillo","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2008.02.004_bib106","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1182\/blood-2006-08-039909","article-title":"Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis","volume":"109","author":"Kroger","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2008.02.004_bib107","doi-asserted-by":"crossref","first-page":"7031","DOI":"10.1200\/jco.2007.25.18_suppl.7031","article-title":"TG101348, a potent, highly selective JAK2 inhibitor, inhibits colony formation in stem cells from polycythemia vera patients and prevents JAK2V617F-mediated splenomegaly and death in a mouse model","volume":"25","author":"Hood","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2008.02.004_bib108","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/sj.leu.2404750","article-title":"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L\/K mutations","volume":"21","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2008.02.004_bib109","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","article-title":"MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation","volume":"109","author":"Giles","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2008.02.004_bib110","unstructured":"JAK2-clinical-trials, http:\/\/www.mdanderson.org\/diseases\/mpd\/display.cfm?id=87c544e8-20e2-4ea9-90597291a76c3e16&method=displayfull. JAK2 inhibitor clinical trials in MD Anderson."},{"key":"10.1016\/j.humpath.2008.02.004_bib111","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1046\/j.1600-6143.2003.00281.x","article-title":"The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models","volume":"4","author":"Kudlacz","year":"2004","journal-title":"Am J Transplant"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817708000841?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817708000841?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T03:52:36Z","timestamp":1588737156000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817708000841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":111,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["S0046817708000841"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2008.02.004","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}